Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TKD-012
- Development stage
- Unknown
- Lead developer
- Therakind
- Administration
- Intranasal
01
Overview
TKD-012 is an undisclosed drug candidate being developed by Therakind in collaboration with an unnamed partner. The therapeutic is formulated for intranasal delivery using Therakind's proprietary DriDose® dry powder nasal technology. DriDose® is designed to enable non-invasive, needle-free, and rapid systemic or local drug delivery without requiring active inhalation or coordination of breathing from the patient.
Beyond the preview
Go deeper on TKD-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TKD-012.